EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

A randomized, double-blind, placebo-controlled, parallel group, dose-response study of MR-107A-02 in the treatment of post-surgical dental pain

Todd Mitchell Bertoch, Seth Grisham, Susanne Vogt iD, Scott Haughie, Kathleen Ocasio, Jeffrey P Smith

Pain Medicine · 01.11.2026 · 27 (11) · 1185-1199

DOI: 10.1093/pm/pnag095 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Pain Medicine, online erschienen am 26.07.2026. Verfasst von Todd Mitchell Bertoch und 5 weiteren Autor:innen. Beteiligte Einrichtung: CenExel JBR, Salt Lake City, UT, United States. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Meloxicam, Postoperative Pain, Tooth Extraction. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Viatris.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

MR-107A-02 is a novel, oral meloxicam formulation designed to enhance dissolution and absorption for rapid analgesia in acute pain. It demonstrates a favorable pharmacokinetic profile, with a higher Cmax and shorter Tmax than Mobic® (meloxicam tablets), while maintaining similar overall extent of exposure.

Methods

This phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study assessed the efficacy and safety of MR-107A-02 at doses of 1.25, 5, and 15 mg twice daily (BID) following third molar extraction. The primary endpoint was SPID0–24, analyzed in the mITT population using W6LOCF to account for rescue medication use. Pain intensity and categorical ratings were evaluated using standardized pain scales. Onset of perceptible and meaningful pain relief were measured using the double-stopwatch technique. Effect sizes and associated standard errors, p-values, and 95% CIs were estimated using an Emax model.

Results

Among 110 participants, MR-107A-02 demonstrated positive dose-dependent analgesia, with mean SPID0-24 Emax values of 70.7 (1.25 mg), 86.7 (5 mg), and 94.8 (15 mg), versus 52.0 for placebo. Significant improvement in SPID0-24 occurred at 5 mg and 15 mg versus placebo (p < .001). The 15 mg dose achieved perceptible and meaningful pain relief within 0.6 and 1.5 hours, respectively, and had the lowest rescue medication use (29.6%) compared to 42.9%, 57.1%, and 74.1% in the 1.25 mg, 5 mg, and placebo. No severe TEAEs, SAEs, or discontinuations were reported.

Conclusions

MR-107A-02 was generally well tolerated and demonstrated dose-dependent efficacy, with the 15 mg BID dose providing rapid analgesia and a reduction in rescue medication use. Clinicaltrial.gov identifier NCT05317312 https://clinicaltrials.gov/study/NCT05317312

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory Agents, Non-SteroidalMeloxicamPostoperative PainTooth ExtractionAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultDose-Response Relationship, DrugDouble-Blind MethodPain MeasurementTreatment Outcome

Stichwörter der Autor:innen

acute painfast-releasemeloxicamrapid analgesiasafety

Substanzen

Anti-Inflammatory Agents, Non-SteroidalMeloxicam

Autor:innen und Institutionen

  • CenExel JBR, Salt Lake City, UT, United States.
  • Viatris, Bad Homburg, Hessen, Germany.
  • Viatris/Mylan Pharma, Sandwich, Kent, United Kingdom.
  • Viatris Inc., Canonsburg, PA, United States.
  • Viatris, Morgantown, WV, United States.

ORCID-Profile: Susanne Vogt

Förderung

  • Viatris

Zitieren

APA

Bertoch, T. M., Grisham, S., Vogt, S., Haughie, S., Ocasio, K., & Smith, J. P. (2026). A randomized, double-blind, placebo-controlled, parallel group, dose-response study of MR-107A-02 in the treatment of post-surgical dental pain. Pain Medicine, 27(11), 1185-1199. https://doi.org/10.1093/pm/pnag095

Vancouver

Bertoch TM, Grisham S, Vogt S, Haughie S, Ocasio K, Smith JP. A randomized, double-blind, placebo-controlled, parallel group, dose-response study of MR-107A-02 in the treatment of post-surgical dental pain. Pain Medicine. 2026;27(11):1185-1199. doi:10.1093/pm/pnag095

BibTeX
@article{Bertoch2026,
  author = {Bertoch, Todd Mitchell and Grisham, Seth and Vogt, Susanne and Haughie, Scott and Ocasio, Kathleen and Smith, Jeffrey P},
  title = {A randomized, double-blind, placebo-controlled, parallel group, dose-response study of MR-107A-02 in the treatment of post-surgical dental pain},
  journal = {Pain Medicine},
  year = {2026},
  volume = {27},
  number = {11},
  pages = {1185--1199},
  doi = {10.1093/pm/pnag095}
}
Kostenlos starten →